Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.32 |
| ▸ | FPR2 | P25090 | 2/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12880537 | 0.92 | ALDH1A1 (0.35) | JAK2JAK1TYK2JAK3PIK3CB | |
| SCHEMBL12880526 | 0.88 | JAK2 (0.39) | JAK2JAK1TYK2JAK3PIK3CB | |
| SCHEMBL12880545 | 0.84 | LMNA (0.34) | PIK3CBPIK3CDPIK3CAPIK3CGRPS6KA3 | |
| SCHEMBL12880548 | 0.84 | GRIA2 (0.37) | PIK3CBPIK3CARPS6KA3CYP1A2GRIA2 | |
| SCHEMBL12880556 | 0.84 | GRIA2 (0.34) | PIK3CACYP1A2GRIA2GRIN1GRIN2A | |
| SCHEMBL13512865 | 0.83 | MEN1 (0.35) | JAK2JAK1TYK2JAK3GRIA2 | |
| SCHEMBL12880540 | 0.82 | ALDH1A1 (0.33) | PIK3CAAKT1CYP1A2GRIA2GRIN1 | |
| SCHEMBL12880546 | 0.81 | MEN1 (0.40) | PIK3CBPIK3CACYP1A2GRIA2GRIN1 | |
| SCHEMBL12880555 | 0.81 | IDO1 (0.34) | PIK3CAAKT1CYP1A2GRIA2GRIN1 | |
| SCHEMBL12880539 | 0.81 | PIK3CA (0.34) | PIK3CDPIK3CAAKT1CYP1A2GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212324-B1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LTD (AU) | 2014-03-26 | — | — | EP | claimed |
| EP-2759544-A1 | Compounds having antiviral properties | Avexa Limited (AU) | 2014-07-30 | — | — | EP | disclosed |
| EP-2759544-A1 | Compounds having antiviral properties | Avexa Limited (AU) | 2014-07-30 | — | — | EP | disclosed |
| EP-2212324-B1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| EP-2212324-B1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
| WO-2010000032-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | JAK2 2211/4885JAK1 782/4885TYK2 4220/4885 |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | JAK2 2211/4885JAK1 782/4885TYK2 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.